Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + ibrutinib + rituximab
- Development stage
- Phase 2
- Lead developer
- Hackensack Meridian Health
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Venetoclax + ibrutinib + rituximab is a combination therapy regimen being investigated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The regimen combines venetoclax, a selective BCL-2 inhibitor that restores the apoptotic process in cancer cells; ibrutinib, a covalent BTK inhibitor that blocks B-cell receptor signaling pathways essential for malignant B-cell survival; and rituximab, an anti-CD20 monoclonal antibody that facilitates immune-mediated clearance of B-cells. This triplet approach, spearheaded by Hackensack Meridian Health in clinical trials, aims to overcome resistance mechanisms and improve clinical outcomes in aggressive non-Hodgkin lymphomas by simultaneously targeting multiple survival nodes.
- Brand names
- Venclexta + Imbruvica + Rituxan
- Other names
- Venetoclax + Ibrutinib + Rituximab combination
02
Targets
Beyond the preview
Go deeper on venetoclax + ibrutinib + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + ibrutinib + rituximab.